Strategic Planning for Drug Regulatory Science in the United States and Its Enlightenments to China

摘要/Abstract

摘要： Objective To study the strategic planning of drug regulatory science, the effectiveness and role of policy implementation in the United States so as to gain insights and make suggestions for further improving the strategic planning of drug regulatory science in China. Methods Literature research method and comparative research method were used to compare and analyze the strategic planning of regulatory science in China and the United States. Results and Conclusion Drawing on the US experience, China should set goals based on mission and vision and identify problems, knowledge gaps, and key areas, then concrete measures can be taken to advance regulatory science.

关键词: the United States, drug, regulatory science, strategic planning

Abstract: Objective To study the strategic planning of drug regulatory science, the effectiveness and role of policy implementation in the United States so as to gain insights and make suggestions for further improving the strategic planning of drug regulatory science in China. Methods Literature research method and comparative research method were used to compare and analyze the strategic planning of regulatory science in China and the United States. Results and Conclusion Drawing on the US experience, China should set goals based on mission and vision and identify problems, knowledge gaps, and key areas, then concrete measures can be taken to advance regulatory science.

Key words: the United States, drug, regulatory science, strategic planning

Chang Yingnan, Gong Jingran, Chang Senhao, Chen Yuwen. Strategic Planning for Drug Regulatory Science in the United States and Its Enlightenments to China[J]. 亚洲社会药学, 2023, 18(2): 91-97.

Chang Yingnan, Gong Jingran, Chang Senhao, Chen Yuwen. Strategic Planning for Drug Regulatory Science in the United States and Its Enlightenments to China[J]. Asian Journal of Social Pharmacy, 2023, 18(2): 91-97.

[1]	Cui Yihang, Chen Binbin, Sun Lihua. Study on Problems and Countermeasures in the Management of Spot Check of Chinese Herbal Pieces[J]. 亚洲社会药学, 2023, 18(2): 107-115.
[2]	Li Qiao, Wang Su, Wang Aili, Wu Di, Chen Yuwen. Enlightenment of COVID-19 Treated by Botanical Drugs on the Development of Drugs for Rare Diseases in China[J]. 亚洲社会药学, 2023, 18(2): 137-148.
[3]	Cui Li, Xing Hua. Enlightenment and Suggestions on the Construction of Information Platform and Processing Mechanism of Drug Shortages in Developed Countries to China[J]. 亚洲社会药学, 2023, 18(2): 177-186.
[4]	Li Qiao, Wang Aili, Wu Di, Chen Yuwen. Analysis of Adverse Reactions in the Treatment of COVID-19 with Three Chinese Patent Medicines and Three Herbal Formulas [J]. 亚洲社会药学, 2023, 18(1): 8-16.
[5]	Lv Xiaowen, Huang Zhe. Present Situation and Enlightenment of Post-Approval Change Management of Drugs in China, USA and EU [J]. 亚洲社会药学, 2023, 18(1): 17-23.
[6]	Wang Guanjie, Shao Mingli. Research on the Development of Drug Regulatory Science in China [J]. 亚洲社会药学, 2022, 17(4): 285-290.
[7]	Zhao Shanshan, Zhang Boquan, Wang Hongyun. The Expanding Roles of Hospital Pharmacists in Clinical Drug Trials in China[J]. 亚洲社会药学, 2022, 17(3): 229-235.
[8]	Liu Fuyao, Sun Lihua. Research on the Price Level of Drugs in Short Supply in China[J]. 亚洲社会药学, 2022, 17(3): 243-252.
[9]	Li Siwen , Yang Yue. The Impact of Generic Drug Consistency Evaluation Policy on Pharmaceutical Enterprises [J]. 亚洲社会药学, 2022, 17(2): 104-114.
[10]	Li Yanying , Huang Zhe, Lian Guiyu. Drug Regulatory Science in EU and Its Enlightenment to China[J]. 亚洲社会药学, 2022, 17(2): 115-119.
[11]	Zhou Ziyang, Ma Jia, Liu Fuyao, Liu Yuhan, Sun Lihua. Cause Analysis and Preventive Measures of Drug Shortage [J]. 亚洲社会药学, 2022, 17(2): 120-131.
[12]	Wang Chen, Chen Chuhan, Liu Yuhan, Sun Lihua. Study on the Matching Degree between Essential Drug List and the Provisions on Drug Coverage in Tertiary Hospitals[J]. 亚洲社会药学, 2022, 17(1): 11-14.
[13]	Yang Dianzheng, Xu Wenxiu, Qi Yun, Yang Yue. Strategic Research on Pharmaceutical Enterprises’Participation in National Drug Centralized Procurement[J]. 亚洲社会药学, 2022, 17(1): 15-22.
[14]	Li Yunlong, Ning Bowen, Yuan Hongmei. Suggestions on Foreign Pharmaceutical Enterprises Dealing with China’s Drug Centralized Procurement – Taking the First Batch of Implementation Results as an Example[J]. 亚洲社会药学, 2022, 17(1): 23-33.
[15]	Su Na , Tian Lijuan. Analysis and Enlightenment of Pediatric Drug Registration Data in China[J]. 亚洲社会药学, 2022, 17(1): 34-38.

亚洲社会药学